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Efficacy of human papillomavirus (HPV) vaccines promises to control HPV infections. However, HPV vaccination programs may lay
bare an ecological niche for non-vaccine HPV types. We evaluated type-replacement by HPV type and vaccination strategy in a
community-randomized trial executed in HPV vaccination na€ıve population. Thirty-three communities were randomized to gender-
neutral vaccination with AS04-adjuvanted HPV16/18 vaccine (Arm A), HPV vaccination of girls and hepatitis B-virus (HBV) vaccination
of boys (Arm B) and gender-neutral HBV vaccination (Arm C). Resident 1992-95 born boys (40,852) and girls (39,420) were invited.
11,662 boys and 20,513 girls were vaccinated with 20–30% and 45–48% coverage, respectively. HPV typing of 11,396 cervicovagi-
nal samples was performed by high throughput PCR. Prevalence ratios (PR) between arms and ranked order of HPV types and odds
ratio (OR) for having multiple HPV types in HPV16 or 18/45 positive individuals were calculated. The ranked order of HPV types did
not significantly differ between arms or birth cohorts. For the non-HPV vaccinated 1992–1993 birth cohorts increased PR, between
the gender-neutral intervention versus control arms for HPV39 (PRA 1.84, 95% CI 1.12–3.02) and HPV51 (PRA 1.56, 95% CI 1.11–
2.19) were observed. In the gender-neutral arm, increased clustering between HPV39 and the vaccine-covered HPV types 16 or 18/45
(ORA1655.1, ORA18/45511.4) was observed in the non-HPV vaccinated 1994–1995 birth cohorts. Comparable clustering was seen
between HPV51 and HPV16 or HPV18/45 (ORB1654.7, ORB18/4554.3), in the girls-only arm. In conclusion, definitively consistent
postvaccination patterns of HPV type-replacement were not observed. Future occurrence of HPV39 and HPV51 warrant investigation.
In clinical phase III trials the three licensed human papillo-
mavirus (HPV) vaccines have been very efficacious (92–
100%) against persistent cervical infections and high-grade
squamous intraepithelial lesions (HSIL) caused by the vaccine
included HPV types.1,2 The bivalent HPV16/18 and quadriva-
lent HPV6/11/16/18 vaccines have been shown to protect
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also against HSIL associated with high-risk HPV types 31
and HPV types 31, 33 and 45, respectively,3,4 presumably due
to cross-neutralizing antibodies induced by the vaccines.5
A concern has, however, been raised, that following imple-
mentation of national HPV vaccination programs the result-
ing reduction in the prevalence of vaccine-covered HPV
types could clear the ecological niche for the non-targeted
HPV types.6 In agreement, type-replacement has been
observed in a number of countries following pneumococcal
vaccination.7 However, thus far HPV type-replacement has
not been observed at the individual level among HPV vacci-
nated females with low vaccination coverage in the target
population.8,9 A prerequisite of HPV type-replacement, that
is, competition between HPV types in unvaccinated popula-
tions, has not been commonly found.10–12 Implementation of
national HPV vaccination programs, however, tends to
increase prevalence of some non-vaccine covered HPV types
suggesting type-replacement.13
HPV epidemiology of vaccination-na€ıve populations
shows that multiple HPV type infections are rare in women
with normal cytology (<3%),14 very common in women with
precancer lesions (15–41%)15 and again rare in women with
HPV-related cervical cancer (<12%).16 In this study, we
explored the possible signs of type-replacement by comparing
occurrence of single and multiple HPV types up to five years
after community-randomized introduction of gender-neutral
or girls-only HPV vaccination with moderate vaccination
coverage.
Materials and Methods
Study design
The material was obtained from the community randomized
trial of the ASO4-HPV-16/18 vaccine (CervarixVR ) sponsored
by GlaxoSmithKline.17,18 Briefly, all 80,272 resident Finnish
or Swedish speaking boys and girls as identified using the
population register were invited in 33 Finnish communities
randomly assigned to one of three study arms (Fig. 1): Arm
A was gender-neutral, Arm B was gender-specific and Arm C
served as the control arm. In the Arm A, 90% of all the par-
ticipants in each community were randomly selected to
receive CervarixV
R
and 10% to receive Engerix-BTM. In the
Arm B, 90% of the female study population in each commu-
nity were randomly selected to receive CervarixVR and 10% to
receive Engerix-BTM, whilst the males all received Engerix-
BTM. In the Arm C, all of the participants were given
Engerix-BTM. The vaccination status of all the participants in
Arm A and all the female participants in Arm B were
receiver-blinded.
In total, 32,175 participants born in 1992–1995 were ini-
tially recruited with informed parental/guardian consent in to
the 3 study arms (20,514 females and 11,661 males) at the
study baseline, in 2007–2009. Ninety-nine point four percent
received three vaccine doses. All females from the study com-
munities, both participants and non-participants were invited
to a follow-up visit between the years 2010–2014, at the age
of 18.5–19 years, within 3–5 years from vaccination. A total
of 14,518 females attended this follow-up visit: 4,922 from
Arm A, 5,247 from Arm B and 4,349 from Arm C. During
the follow-up session, a self-collected cervicovaginal sample
was obtained and a cervical sample was obtained by a study
nurse. The participants consented to take part in Chlamydia
trachomatis screening, and participants completed a question-
naire about life-style factors, mobility and their sexual
health.17 Residential history data was also available from the
population registry.
The ethical committees for the Pirkanmaa and Pohjois-
Pohjanmaa hospital districts granted the HPV-040 study
(EUDRA-CT-2007–001731-55, NCT00534638) approval in
2007, and the ancillary C. trachomatis screening study (111/
2009) approval in 2009, respectively.
Laboratory analysis
The samples collected at the first follow-up visit were ana-
lyzed using modified general primer (MGP) PCR followed by
matrix-assisted laser desorption time-of-flight (MALDI-TOF)
mass spectrometry (MS).19,20 The MGP PCR used type-
specific consensus primers to replicate specific types of HPV
DNA. Every type-specific consensus primer used had a par-
ticular molecular weight, which was detected using MALDI-
TOF MS to identify the presence of HPV6, 11, 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59 and 66.20 Confirmative analysis
of samples positive for HPV 11 was performed using MGP
PCR followed by Luminex,19 due to interactions between
HPV11 and 89 for the HPV11 primer, in order to correctly
distinguish between HPV11 and HPV89.
Statistical analysis
The prevalence ratios [PR with 95% confidence interval (CI)]
of specific HPV types (HPV6, 11, 16, 18, 31, 33, 35, 39, 45,
What’s new?
Vaccination against high-risk human papilloma virus (HPV) strains is efficacious, but possible resurgence of non-targeted viral
strains is a concern. The authors performed a community-randomized study with 20–50% vaccination coverage in 1992–95
birth cohorts of 80,000 adolescents. They compared gender-neutral or girls-only HPV16/18 vaccination or hepatitis B-virus
vaccination in 11 communities, and a consistent pattern of HPV type-replacement was not found. However, occurrence of
HPV39 and HPV51 types warrants further observation in the future.
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51, 52, 56, 58, 59 and 66) between Arm A and C, and Arm
B and C were estimated by log-binomial regression.
As a sensitivity analysis odds ratios (OR with 95% CI) of
having another HPV type among those positive for the vac-
cine HPV types 16 or 18, or the strictly vaccine covered type
HPV45 were estimated by arm using those negative for
HPV16 or for HPV18/45 as the reference group applying
binomial logistic regression. The PR and OR estimates were
adjusted for participant mobility, for community-level preva-
lence of regular smoking and for individual level C. tracho-
matis status, reflecting the risk-taking behavior.18
The between-arms relationships of HPV type prevalence
ranks were assessed by comparing Spearman’s rank correla-
tion coefficients.
In our first impact of vaccination strategies article,18 herd
effects at the follow-up of age 18.5 years were observed to be
stronger in the later than earlier age cohorts. Thus, all the
above-mentioned estimates were computed separately for
1992–1993 and 1994–1995 cohorts.
Both participants who had migrated from control arm
communities to Arm A or B, and those who had migrated
from Arm A or B communities to control Arm C, were
excluded from the analysis (N5 92). However, participants
moving from Arm A to B (N5 31), and Arm B to A
(N5 34) were included. Due to the follow-up invitations of
non-participants, the HBV vaccinated:unvaccinated ratio was
different in Arm C compared with Arm A and Arm B in
non-HPV-vaccinated women. The difference was corrected
for in the PR and OR estimation (Fig. 2 and Table 3):
Twenty-one samples, one eighth of HBV vaccinated Arm C
women each, were randomly selected from 44 birth year-
community strata. Each sample was joined with all Arm C
unvaccinated women. The PR estimate was the mean of 21
random sample-specific estimates. The 95% CIs were esti-
mated by a homogenization-based approach, described in
Ref. 18.
The statistical analyses were conducted using SPSS statisti-
cal software version 23.0 (IBM Corp, Armonk, NY) and R
statistical software version 3.3.2 with Epi package (version
2.15, The R Foundation; https://www.r-project.org/). The val-
ues of trigamma functions for homogenization-based CIs
were calculated using SAS 9.4 (SAS Inst. Inc., Cary, NC).
Results
Demographics and behavioral characteristics of the trial
arms
Entire 1992–1995 Finnish and Swedish speaking female and
male birth cohorts of the 33 randomized communities were
invited to the trial on the effectiveness of HPV vaccination
strategies (Fig. 1). Participation rates at the study baseline
and attendance rates to the follow-up visit at study end were
equal in the different groups of vaccination participants and
attendees of the cytological sampling (Fig. 1).
Demographic and risk-taking behavior characteristics of
the study arms revealed no major differences between the
HPV vaccinated and non-HPV vaccinated women (Table 1).
However, more non-HPV vaccinated women had 5 or more
life-time partners (19.2 and 16.7%) in intervention Arms A
and B with gender-neutral and girls-only HPV vaccination,
respectively, than in the control Arm C (13.7%) with HBV
vaccination. In addition, more non-HPV vaccinated Arm A
participants were current smokers (34.2%) in comparison
to the non-HPV vaccinated Arm C participants (30.3%)
(Table 1).
Figure 1. Flow chart of the community-randomized trial. [Color figure can be viewed at wileyonlinelibrary.com]
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HPV PRs in HPV vaccinated and non-HPV vaccinated
women
The effect of HPV vaccination in the HPV16/18 vaccinated
1994–1995 birth cohorts extended over five HPV types: 16/
18/31/33/45 in the PR analysis (Figs. 2a and 2b). As for the
nonvaccine covered HPV types, no major differences in the
PRs between the intervention Arms A or B and the control
Arm C were observed in the non-HPV16/18 vaccinated
women (Figs. 2c and 2d). Amongst increased PRs there, how-
ever, was a pattern of 3 out of 4 significantly increased
HPV51 PRs in both vaccinated and non-HPV vaccinated
1992–1993 birth cohorts (Figs. 2a–2c).
In the 1992–1993 birth cohort the PR between the non-
HPV vaccinated participants of the gender-neutral
Figure 2. PR (95% CI) estimates of HPV types in HPV16/18 vaccinated, (a) and (b), and in non-HPV vaccinated, (c) and (d), stratified by
birth cohort and adjusted for mobility, and smoking and C. trachomatis status. (a) Arm A versus Arm C, (b) Arm B versus Arm C, (c) Arm A
versus Arm C and (d) Arm B versus Arm C.
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intervention Arm A versus the control Arm C for HPV39
(PRA 1.84, 95% CI 1.12–3.02) was significantly different from
unity (Fig. 2c). In the girls-only intervention Arm B versus
the control Arm C PRs for HPV6 (PRB 1.74, 95% CI 1.19–
2.56) and for HPV52 (PRB 1.60, 95% CI 1.09–2.36) also were
increased (Fig. 2d). In addition, in the 1992–1993 birth
cohorts between the non-HPV vaccinated participants the
PRs for HPV33 tended to be increased in both intervention
arms (PRA 1.56, 95% CI 0.83–2.93, PRB 1.86, 95% CI 1.05–
3.27; Figs. 2c and 2d).
With the exception of HPV45 (PRA 1.70, 95% CI 1.02–
2.82 vs. PRB 0.80, 95% CI 0.42–1.51), no notable discrepancy
in the PRs were observed between the intervention Arms A
and B, and control Arm C in the 1994–1995 birth cohorts.
Figure 2. Continued.
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Multiple infections in HPV vaccinated and non-HPV
vaccinated women
The PR observations of note were further elaborated by a
sensitivity analysis on clustering of specific HPV types. Clus-
tering of a number of HPV types with the vaccine or
vaccine-covered HPV types 16 and HPV18/45 was evaluated
as OR of being positive for another HPV type, for HPV16 or
HPV18/45 positive versus HPV16 or HPV18/45 negative
women. ORs for those HPV types with significantly increased
PRs (HPV6/33/39/45/51/52/66) were calculated in HPV vac-
cinated women (Table 2) and non-HPV vaccinated women
(Table 3). We observed occasional, nonsignificant, clustering
Table 1. Characteristics of 1992–1995 born participants attending the first follow-up visit at 18.5 years of age by study arm and vaccination
status
Arm A Arm B Arm C
HPV vac Non-HPV vac1 HPV vac Non-HPV vac1 HBV vac Non-HPV vac1
1992–1995 1992–1995 1992–1995 1992–1995 1992–1995 1992–1995
Characteristic N (%) N (%) N (%) N (%) N (%) N (%)
Lives in study community2
Yes 3,257 (90.6) 814 (79.0) 3,432 (92.7) 975 (82.6) 3,154 (92.0) 3,584 (89.9)
No 287 (7.99) 203 (19.7) 251 (6.78) 188 (15.9) 246 (7.18) 372 (9.33)
Missing 49 (1.36) 14 (1.36) 19 (0.51) 17 (1.44) 28 (0.82) 32 (0.80)
Mobility3
Semi-Urban citizen at study entry 2,573 (87.9) 869 (94.1) 2,455 (80.3) 874 (82.0) 2,407 (85.8) 2,926 (86.7)
First follow-up community different 356 (12.2) 54 (5.9) 604 (19.7) 192 (18.0) 398 (14.2) 449 (13.3)
Mean age at sexual debut4 16.4 (1.7)5 na 16.3 (1.7)5 na 16.4 (1.7)5 na
No. of life-time partners2
0 838 (23.3) 202 (19.6) 811 (21.9) 231 (19.6) 776 (22.6) 871 (21.8)
1 884 (24.6) 228 (22.1) 989 (26.7) 309 (26.2) 989 (28.9) 1,146 (28.7)
2 572 (15.9) 161 (15.6) 587 (15.9) 174 (14.7) 546 (15.9) 614 (15.4)
3 435 (12.1) 103 (9.99) 407 (11.0) 122 (10.3) 367 (10.7) 418 (10.5)
4 289 (8.04) 92 (8.92) 292 (7.89) 98 (8.31) 243 (7.09) 303 (7.60)
5 or more 534 (14.9) 198 (19.2) 583 (15.7) 197 (16.7) 458 (13.4) 546 (13.7)
Missing 41 (1.14) 47 (4.56) 33 (0.89) 49 (4.15) 49 (1.43) 90 (2.26)
C. trachomatis status6
C. trachomatis positive 102 (3.48) 38 (4.12) 95 (3.11) 44 (4.13) 83 (2.96) 109 (3.23)
C. trachomatis negative 2,822 (96.3) 881 (95.4) 2,959 (96.7) 1,017 (95.4) 2,715 (96.8) 3,254 (96.4)
Missing 5 (0.17) 4 (0.43) 5 (0.16) 5 (0.47) 7 (0.25) 12 (0.36)
Smoking habit2
Never smoked 2,108 (58.7) 587 (56.9) 2,296 (62.0) 733 (62.1) 2,111 (61.6) 2,442 (61.2)
Quit smoking 232 (6.46) 80 (7.76) 253 (6.83) 90 (7.63) 250 (7.29) 301 (7.55)
Current 1,215 (33.8) 353 (34.2) 1,115 (30.1) 342 (29.0) 1,038 (30.3) 1,208 (30.3)
Current other than cigarettes 7 (0.19) 2 (0.19) 6 (0.16) 2 (0.17) 0 (0) 3(0.08)
Missing 31 (0.86) 9 (0.87) 32 (0.86) 13 (1.10) 29 (0.84) 34 (0.85)
Vaccination coverage7
<40% 334 (11.4) na 516 (17.2) na 169 (6.00) na
40–50% 919 (31.4) na 1,659 (55.3) na 691 (24.6) na
>50% 1,676 (57.2) na 826 (27.5) na 1,945 (69.3) na
1Non-HPV vaccinated women consist of both HBV vaccinated and unvaccinated women.
2Questionnaire data obtained at the age of 18.5–19 years.
3Residential history data obtained from Finnish Population Registry.
4Questionnaire data obtained at the age of 22 years.
5SD.
6Laboratory analysis data obtained at the age of 18.5–19 years.
7Community-wise vaccination coverage.
Abbreviations: Arm A5 gender-neutral HPV-16/18 vaccination; Arm B5 girls-only HPV-16/18 vaccination; Arm C5HBV vaccination.
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between HPV39 and the vaccine-covered HPV16 or HPV18/
45 both in the non-HPV vaccinated Arm A and Arm B
women (ORA16/92–935 4.9, ORA16/94–955 5.1, ORA18/45/94–955
11.4, ORB16/94–955 4.6 and ORB18/45/94–955 3.9), and HPV vac-
cinated Arm B women (ORB16/94–955 5.3 and ORB18/45/92–935
9.7). As for HPV51, we observed significant clustering
with HPV16 in the girls-only Arm B births cohorts 1994–95
(ORB16/94–955 4.7, 95% CI 2.10–10.5, vs. ORC16/94–955 1.2, 95%
CI 0.64–2.07). The model did not always converge, and the CIs
overlapped those of the control Arm C estimates.
For HPV33, no consistent pattern of increased ORs was
observed in the HPV vaccinated women or in the non-HPV
vaccinated women (Tables 2 and 3). Likewise, no consistently
increased ORs were observed for HPV6 or HPV52 in the
non-HPV vaccinated women or in the HPV vaccinated
women (Tables 2 and 3).
Post vaccination HPV type-distributions by vaccination
strategy
To further evaluate the impact of HPV vaccination generated
herd effect on the HPV population biology we compared the
ranked distribution of non-vaccine covered HPV types in the
non-vaccinated female 1992-birth cohort (first vaccinated
birth cohort) and 1995-birth cohort (last vaccinated birth
cohort). Among both the 1992 and 1995 birth cohorts the
correlation coefficients of HPV type distributions between
Arms A (gender-neutral vaccination) and C, Arms B (girls-
only vaccination) and C were high (0.79 to 0.95) and statisti-
cally indistinguishable (Fig. 3).
Discussion
Sporadic HPV39 and 51 occurrence but, no patterns sugges-
tive of type-replacement following vaccination with the biva-
lent HPV16/18 vaccine and up to 20% coverage in boys and
50% coverage in girls were found in our population-based,
community-randomized trial.
Despite of HPV16 epidemic documented in Finland in the
1980s and 1990s,21,22 the prevalence rates of HPV types are
relatively stable with HPV16 dominating.14,23 This seemed to
be true also for the ranked order of oncogenic HPV type
prevalence rates, especially in our control Arm C, devoid of
any intervention. We have previously shown significant herd
effect against HPV18, 31 and 33 in our community random-
ized trial.18 We now used the community randomized trial
setting to discover changes in the HPV type specific occur-
rence in the vaccinated communities (Arm A and Arm B)
subject to moderate vaccination coverage. Due to vaccine
induced direct and cross-protection,4,24 the overall prevalence
of HPV types 16/18/31/33/35/45 decreased in trial Arms A
and B. Comparing the oldest and the youngest birth cohorts
Table 2. OR (95% CI) estimates of HPV type 16 (a) or HPV18/45 (b) coinfections with other HPV types in HPV vaccinated females (Arms A
and B) and HBV vaccinated females (Arm C) by vaccination strategy [gender neutral (arm A), girls-only (arm B) and no HPV vaccination (arm
C)] stratified by birth cohort and adjusted for mobility, smoking and C. trachomatis positivity using HPV16 PCR negatives (a) and HPV18/45
PCR negatives (b) as reference groups
OR (95% CIs)
Arm A Arm B Arm C
HPV Type 1992–1993 1994–1995 1992–1993 1994–1995 1992–1993 1994–1995
(a) 16 (neg) as reference group
6 na 13.1 (2.04–84.1) 2.30 (0.28–18.7) 3.22 (0.39–26.5) 4.42 (2.34–8.37) 4.80 (2.64–8.7)
18 na na na na 4.18 (2.12–8.27) 5.93 (3.14–11.2)
33 na na na na 1.19 (0.36–3.94) 4.42 (1.96–9.95)
39 na na na 5.27 (0.63–44.3) 2.09 (0.79–5.50) 3.85 (1.77–8.37)
45 na na na na 2.17 (0.74–6.37) 2.33 (0.77–7.04)
51 na 2.90 (0.29–28.8) 3.62 (0.74–17.7) na 2.02 (0.97–4.20) 3.20 (1.80–5.67)
52 na na 2.75 (0.34–22.5) 3.49 (0.42–29.0) 3.90 (1.99–7.65) 4.14 (2.17–7.90)
66 2.84 (0.35–23.1) 5.62 (0.56–56.3) na 3.29 (0.40–27.0) 3.32 (1.49–7.43) 3.12 (1.53–6.36)
(b) 18/45 (neg) as reference group
6 2.39 (0.30–19.1) 3.22 (0.37–28.2) 1.28 (0.16–10.2) 4.63 (0.51–42.1) 5.51 (2.86–10.6) 2.26 (1.07–4.78)
16 na na na na 3.89 (2.14–7.06) 4.79 (2.69–8.52)
33 na na na na 4.62 (2.01–10.6) 1.94 (0.65–5.79)
39 3.19 (0.40–25.6) na 9.65 (2.52–37.0) na 2.99 (1.19–7.51) 1.23 (0.37–4.12)
51 1.25 (0.16–9.85) na 3.19 (0.85–12.0) 2.44 (0.26–23.2) 5.41 (2.91–10.1) 2.75 (1.45–5.19)
52 na na 6.50 (1.67–25.4) 5.60 (0.61–51.3) 4.27 (2.06–8.86) 4.16 (2.08–8.32)
66 5.13 (1.08–24.3) 3.98 (0.44–35.7) na na 4.29 (1.94–9.49) 3.57 (1.74–7.35)
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no major differences in PRs between arms or the ranked
order of prevalence rates for non-vaccine covered HPV types
were observed in non-HPV vaccinated women. With the lat-
ter approach, we identified changes on C. trachomatis sero-
types over decades due to population movements.25 In this
study, post-vaccination follow-up time may, however, have
been too short and the sample size limited, to observe
changes in the distribution of nonvaccine oncogenic HPV
types.
A recent meta-analysis of 9 studies found slightly
increased prevalence rates for HPV types 39 and 52 when
comparing pre- and post-vaccination type-distributions.13
Comparing intervention communities of the gender-neutral
and girls-only arms with the non-intervention communities
of the control arm was a comparable approach. We found
significantly increased HPV39 and HPV51 PRs in the
gender-neutral Arm A communities among the 1992–1993
birth cohorts, and found some evidence suggesting increased
clustering of HPV39 in HPV16 or HPV18/45 positive women
in the gender-neutral intervention communities among the
1994–1995 born. As for HPV51, comparable clustering was
observed only in the girls-only arm. The risk of being
HPV39 or HPV51 positive among HPV16 or HPV18/45
positive women was adjusted for mobility, smoking and
C. trachomatis positivity (a surrogate of risk-taking sexual
behavior) but the fact that the observations were not birth
cohort or intervention arm specific may not support type-
replacement. Furthermore, comparable Arm A specific clus-
tering in the 1994–1995 born women was observed for
HPV52 which showed a PR increase in the girls-only Arm B
communities and 1992–1993 birth cohort only.
Post-vaccination evidence of type replacement occurring
in the clustering of multiple types approach is defined as
increased clustering in the intervention arms as compared
with the controls arms, as the replacing type gains the com-
petitive advantage over the vaccine protected type. Further-
more, clustering of multiple HPV infections is one of the
most sensitive ways of looking for changes in the population
biology of HPV types although subject to bias based on
behavioral differences (risk-taking factors) and possible corre-
lation of the occurrence of HPV types.26,27 Thus, we used it
but only as a sensitivity analysis to achieve more insight into
a priori hypothesized prevalence rate ratio differences. Addi-
tionally, despite the large sample size, the number of some
rarer HPV type-specific infections were relatively few in
some cases, therefore limiting the power of this analysis. As
for HPV16, its unique clearance characteristics make it diffi-
cult to compare the different HPV specific clustering
Table 3. OR (95%CI) estimates of human papilloma virus (HPV) type 16 (a) or HPV 18/45 (b) coinfections with other HPV types in non-HPV
vaccinated females by vaccination strategy [gender neutral (arm A), girls-only (arm B) and no HPV vaccination (arm C)] stratified by birth
cohort and adjusted for mobility, smoking and C. trachomatis positivity using HPV16 PCR negatives (a) and HPV18/45 PCR negatives (b) as
reference groups
OR (95% CIs)
Arm A Arm B Arm C
HPV Type 1992–1993 1994–1995 1992–1993 1994–1995 1992–1993 1994–1995
(a) 16 (neg) as
reference group
6 3.40 (1.14–10.1) 4.48 (1.62–12.4) 2.35 (0.75–7.38) 3.06 (1.08–8.65) 2.02 (1.03–3.99) 4.22 (2.89–6.19)
18 5.75 (2.07–16.0) 3.44 (0.92–12.9) 1.62 (0.42–6.24) 8.86 (2.69–29.1) 4.61 (3.02–7.03) 3.36 (1.99–5.67)
33 4.42 (1.29–15.2) 5.27 (1.16–24.1) 2.35 (0.48–11.5) 5.32 (1.55–18.2) 2.65 (1.08–6.53) 4.44 (2.27–8.68)
39 4.91 (1.52–15.9) 5.14 (1.54–17.2) na 4.64 (1.17–18.4) na 1.60 (0.72–3.56)
45 7.79 (1.93–31.4) 4.59 (1.36–15.6) 3.42 (0.68–17.2) 1.10 (0.14–8.88) 1.89 (0.78–4.55) na
51 1.12 (0.34–3.64) 2.26 (0.85–6.01) 0.70 (0.15–3.30) 4.69 (2.10–10.5) 1.79 (0.99–3.22) 1.15 (0.64–2.07)
52 0.75 (0.15–3.74) 2.94 (1.03–8.41) 2.79 (0.97–8.02) 4.35 (1.48–12.8) 3.39 (1.98–5.81) 5.16 (3.31–8.04)
66 1.68 (0.43–6.52) 5.29 (1.77–15.8) 2.42 (0.52–11.2) 4.18 (1.27–13.8) 4.58 (2.95–7.13) 2.99 (1.87–4.77)
(b) 18/45 (neg) as
reference group
6 3.70 (1.36–10.1) 7.48 (2.66–21.0) 4.37 (1.69–11.3) 4.40 (1.39–14.0) 4.55 (2.61–7.93) 3.75 (2.46–5.71)
16 6.08 (2.42–15.3) 3.46 (1.19–10.0) 2.36 (0.80–6.92) 4.30 (1.60–11.6) 4.26 (2.92–6.22) 2.04 (1.29–3.20)
33 2.76 (0.73–10.4) 2.54 (0.30–21.8) 1.82 (0.38–8.86) 3.95 (0.82–18.9) 5.65 (2.62–12.2) 2.17 (0.90–5.27)
39 0.54 (0.07–4.36) 11.4 (3.52–36.9) 1.73 (0.20–15.3) 3.87 (0.79–18.9) 3.07 (1.44–6.55) 2.83 (1.40–5.70)
51 1.67 (0.58–4.75) 1.56 (0.44–5.48) 4.26 (1.69–10.8) 4.26 (1.60–11.3) 4.54 (2.99–6.89) 2.68 (1.71–4.21)
52 2.90 (0.97–8.66) 6.37 (2.28–17.7) 4.58 (1.82–11.5) na 3.55 (2.06–6.12) 4.24 (2.58–6.95)
66 3.15 (1.06–9.37) 2.24 (0.49–10.4) 3.38 (0.92–12.5) 5.41 (1.41–20.8) 4.68 (2.95–7.43) 2.68 (1.57–4.55)
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observations.1 Taken together findings from the PR and clus-
tering analyses were not definitively consistent for any HPV
type.
Finally, technical unmasking of HPV52 DNA amongst a
number of other HPV type DNAs following removal of, for
example, HPV16 DNA by vaccination has been described as
one potential bias of surveillance studies provided the PCR
methodology suffers from the “unmasking” phenomenon.26,28
Thus, it is possible that following HPV vaccination the
increased prevalence of non-vaccine HPV types are not
caused by type replacement but rather by unmasking. Con-
cerning oncogenic HPV types our MALDITOF PCR, how-
ever, does not suffer from such problems.20
Previous studies among non-vaccinated population sam-
ples have concluded that HPV type co-infections occur at
random in normal cytology, in cervical pre-cancer and in
cancer lesion patients.12,28–36 Indeed, if significant clustering
of HPV types was observed it was regarded as a bias stem-
ming from the unspecific genotyping of different HPV
types.28,29 Taken together, and in agreement with the previ-
ous studies, despite of sporadic clustering of some high risk
HPV types in HPV16 or HPV18/45 positive women no
definitively consistent patterns suggestive of type-replacement
with non-vaccine HPV types were observed at the population
level approximately up to 5 years post vaccination in this
real-life community-randomized trial with up to 50% vacci-
nation coverage by community.
In conclusion, our vaccination coverage has been high
enough to observe vaccine efficacy and herd effect of HPV
vaccination on the occurrence of HPV types, other than
HPV16.18 As for all other HPV types, the study probably had
ample power to study type-replacement under the selective
pressure from different vaccination strategies. No conclusive
signs of type-replacement were observed, but HPV39 and
HPV51 occurrence warrants further investigation.
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